US4265875A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release suppositories
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1979-10-19
•
Granted: 1981-05-05
•
Expires: 1999-10-19
Abstract
Abstract A slow-release suppository is provided. The slow-release suppository comprises a linear polymer, water and a therapeutically active ingredient.
Inventors
- 👤 Geoffry A. Byrne
- 👤 Ross I. Aylott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 00:53
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/02
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
51 words
A non-dissolving, non-disintegrating slow-release suppository consisting essentially of hydroxypropylmethyl-cellulose, water, and a therapeutically effective amount of a water-soluble therapeutically active ingredient wherein the water is present in an amount of more than 35 parts by weight and the hydroxypropylmethyl-cellulose is present in an amount of less than 65 parts by weight.
Claim 2
Dependent Claim
51 words
A non-dissolving, non-disintegrating slow-release suppository consisting essentially of hydroxypropylmethyl-cellulose, water, and a therapeutically effective amount of a water-soluble therapeutically active ingredient wherein the water is present in an amount of more than 35 parts by weight and the hydroxypropylmethyl-cellulose is present in an amount of less than 65 parts by weight.
Claim 3
Dependent Claim
34 words
The slow-release suppository of claim 1 wherein the amount of hydroxypropylmethyl-cellulose is from 30 to 65 parts by weight, and the amount of water is from about 35 to about 70 parts by weight.
Claim 4
Dependent Claim
36 words
The slow-release suppository of claim 2 wherein the amount of hydroxypropylmethyl-cellulose is from about 30 to about 60 parts by weight, and the amount of water is from about 40 to about 70 parts by weight.
Claim 5
Dependent Claim
24 words
The slow-release suppository of claim 3 wherein there are essentially 50 parts by weight of hydroxypropylmethyl-cellulose and about 50 parts by weight of water.
Claim 6
Dependent Claim
41 words
The slow-release suppository of claim 1 wherein the therapeutically active ingredient is selected from the group consisting of lignocaine hydrochloride, phenylephrine hydrochloride, betamethasone sodium phosphate, sodium prednisolone metasulphobenzoate, di-sodium prednisolone phosphate, methyl-prednisolone sodium succinate, dexamethasone sodium phosphate and hydrocortisone sodium phosphate.
References Cited (Backward Citations)
US108034A
Cited
US1858108A
Cited
US2149005A
Cited
US2155658A
Cited
US2160503A
Cited
US2498374A
Cited
US2726982A
Cited
US3234091A
Cited
US3108043A
Cited
US3170464A
Cited
US3449489A
Cited
US3496938A
Cited
US3443563A
Cited
US3763861A
Cited
US3609102A
Cited
US3640741A
Cited
US3767789A
Cited
US4024073A
Cited
US3875300A
Cited
US3776001A
Cited
US4136162A
Cited
US4136145A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-05-04 | 1984-11-03 | 1985-05-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-05-04 | 1988-11-03 | 1989-05-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-05-04 | 1992-11-03 | 1993-05-05 | $7700.00 | Window Closed / Lapsed |